DIANTHUS THERAPEUTICS INC (DNTH) Forecast, Price Target & Analyst Ratings
NASDAQ:DNTH • US2528281080
79.23 USD
+14.03 (+21.52%)
At close: Mar 9, 2026
77 USD
-2.23 (-2.81%)
After Hours: 3/9/2026, 4:07:24 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DIANTHUS THERAPEUTICS INC (DNTH).
Forecast Snapshot
Consensus Price Target
$76.76
-3.12% Downside
Next Earnings Forecast
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$1.10
Revenue Estimate406.898K
ChartMill Buy Consensus
87.62%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$76.76
Upside
-3.12%
From current price of $79.23 to mean target of $76.76, Based on 21 analyst forecasts
Low
$47.47
Median
$67.32
High
$131.25
Price Target Revisions
1 Month
1.01%
3 Months
11.62%
Price Target Summary
21 analysts have analysed DNTH and the average price target is 76.76 USD. This implies a price decrease of -3.12% is expected in the next year compared to the current price of 79.23.
The average price target has been revised upward by 11.62% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.62%
DNTH was analyzed by 21 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about DNTH.
In the previous month the buy percentage consensus was at a similar level.
DNTH was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-09 | Truist Securities | Maintains | Buy -> Buy |
| 2026-03-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-04 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-02 | Jefferies | Maintains | Buy -> Buy |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-14 | Truist Securities | Initiate | Buy |
| 2025-09-17 | Clear Street | Initiate | Buy |
| 2025-09-12 | Stifel | Maintains | Buy -> Buy |
| 2025-09-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-09 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-09-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-07-02 | William Blair | Initiate | Outperform |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 19, 2026
PeriodQ4 / 2025
EPS Estimate-$1.10
Revenue Estimate406.898K
Revenue Q2Q-59.27%
EPS Q2Q-35.46%
Number of Analysts16
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-0.33%
EPS (3 Months)
-0.80%
Next Earnings Summary
DNTH is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -1.1 USD and the consensus revenue estimate is 406.90K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.826M | 6.235M 120.63% | 2.259M -63.77% | 1.48M -34.48% | 2.351M 58.85% | 34.338M 1,360.57% | 142.8M 315.87% | 496.6M 247.76% | 783.05M 57.68% | 1.115B 42.39% | 1.414B 26.82% | ||
| EBITDA YoY % growth | -78.97M -8.67% | -48.107M 39.08% | -101.768M -111.55% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -80.9M -8.31% | -48.174M 40.45% | -101.864M -111.45% | -162.177M -59.21% | -187.172M -15.41% | -228.54M -22.10% | -229.81M -0.56% | -198.451M 13.65% | 48.808M 124.59% | 259.89M 432.47% | 477.55M 83.75% | 679.36M 42.26% | |
| Operating Margin | N/A | -1,704.67% | -1,633.74% | -7,179.14% | -12,646.75% | -9,720.95% | -669.26% | -138.97% | 9.83% | 33.19% | 42.83% | 48.05% | |
| EPS YoY % growth | -20.64 1.53% | -12.97 37.16% | -2.60 79.95% | -3.74 -43.95% | -3.83 -2.26% | -4.46 -16.66% | -4.73 -5.85% | -5.31 -12.38% | -2.15 59.48% | -1.01 52.84% | 2.53 349.75% | 6.45 154.33% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.10 -35.46% | -0.93 -13.06% | -0.93 -6.06% | -0.97 0.10% | -0.96 12.62% | -0.96 -3.42% | -0.98 -4.92% | -1.00 -3.16% | -1.02 -6.38% |
| Revenue Q2Q % growth | 406.898K -59.27% | 203.419K -82.51% | 217.984K 12.95% | 203.419K -48.63% | 305.419K -24.94% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -51.614M -61.72% | -43.444M -30.94% | -43.46M -24.43% | -45.655M -13.32% | -46.817M 9.29% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-19.75%
EPS Next 5 Year
-15.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.37%
Revenue Next 5 Year
90.74%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
DIANTHUS THERAPEUTICS INC / DNTH Forecast FAQ
Can you provide the average price target for DIANTHUS THERAPEUTICS INC stock?
21 analysts have analysed DNTH and the average price target is 76.76 USD. This implies a price decrease of -3.12% is expected in the next year compared to the current price of 79.23.
When does DIANTHUS THERAPEUTICS INC (DNTH) report earnings?
DIANTHUS THERAPEUTICS INC (DNTH) will report earnings on 2026-03-19, after the market close.
What are the consensus estimates for DIANTHUS THERAPEUTICS INC (DNTH) next earnings?
The consensus EPS estimate for the next earnings of DIANTHUS THERAPEUTICS INC (DNTH) is -1.1 USD and the consensus revenue estimate is 406.90K USD.
What is the number of analysts for DNTH stock?
The number of analysts covering DIANTHUS THERAPEUTICS INC (DNTH) is 21.